What is the significance of angiotensin‑II receptor blockers (ARBs) on the aldosterone‑renin ratio?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ARBs Raise Renin and Can Cause False-Negative ARR Results

ARBs (angiotensin-II receptor blockers) significantly elevate renin levels, which lowers the aldosterone-to-renin ratio (ARR) and can lead to false-negative screening results for primary aldosteronism. 122

Mechanism of Interference

ARBs block the angiotensin-II receptor, which triggers a compensatory increase in renin secretion. This renin elevation artificially lowers the ARR by increasing the denominator of the ratio, potentially masking primary aldosteronism even when aldosterone levels remain inappropriately elevated 22.

Clinical Implications for ARR Interpretation

When ARBs Are Present During Screening:

  • A detectable renin level or low ARR does NOT exclude primary aldosteronism in patients on ARBs 22
  • However, if renin remains undetectable despite ARB therapy, primary aldosteronism is strongly suspected 22
  • This creates a unique interpretive scenario where suppressed renin on an ARB is highly specific for PA

Guideline Recommendations for ARB Management:

Withdraw ARBs for at least 2 weeks before ARR testing when feasible and safe 122. The 2025 Endocrine Society guideline specifically states this 2-week washout period for both ACE inhibitors and ARBs 1.

Practical Algorithm for ARB Management

For initial screening:

  • Discontinuation of ARBs is not strictly required if it would compromise blood pressure control 22
  • You can proceed with screening while on ARBs, but interpret results cautiously

If screening is negative while on ARBs:

  • Repeat testing after withdrawing ARBs for 2 weeks if the patient has moderate-to-high pretest probability (resistant hypertension, hypokalemia) 1
  • This is particularly important if renin is detectable but aldosterone is 5-10 ng/dL 1

Alternative antihypertensives during washout:

  • Use alpha-1 blockers (doxazosin), hydralazine, or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) 22
  • These medications minimally affect the renin-aldosterone axis

Critical Pitfall to Avoid

The most common error is accepting a negative ARR result in a patient with high clinical suspicion (resistant hypertension, hypokalemia) who remains on ARBs. Always repeat testing after appropriate medication adjustment in these cases 1. The renin-raising effect of ARBs can completely obscure the diagnosis, particularly in patients with milder forms of primary aldosteronism where aldosterone levels may not be dramatically elevated 3.

Contrast with Beta-Blockers

Unlike ARBs which raise renin, beta-blockers suppress renin and can cause false-positive results by artificially elevating the ARR 12. This creates the opposite problem and requires different management strategies.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.